<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912558</url>
  </required_header>
  <id_info>
    <org_study_id>BM-011</org_study_id>
    <nct_id>NCT03912558</nct_id>
  </id_info>
  <brief_title>Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients.</brief_title>
  <official_title>Prospective, Open-Label, Non-Comparative, Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butterfly Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butterfly Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of use of the Butterfly Medical's prostatic&#xD;
      retraction device in Benign Prostatic Hyperplasia (BPH) Patients. The study follows patients&#xD;
      implanted with the Butterfly device for up to 1 year after implantation.&#xD;
&#xD;
      Evaluations include recording of safety events and BPH related symptoms by Uroflowmetry tests&#xD;
      and International Prostate Symptom Score (IPSS) questionnaires. The study also assess sexual&#xD;
      quality of life after implantation of the Butterfly device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that&#xD;
      may restrict the flow of urine from the bladder. BPH is a cellular proliferative process of&#xD;
      the prostate, also referred as enlarged prostate.&#xD;
&#xD;
      An estimated 50% of men demonstrate histopathologic BPH by age 60 years. This number&#xD;
      increases to 90% by age 85 years; thus, increasing gland size is considered a normal part of&#xD;
      the aging process.&#xD;
&#xD;
      Approximately half of those diagnosed with histopathologic BPH demonstrate moderate-to-severe&#xD;
      BPH related symptoms (also known as Lower Urinary Tract Symptoms = LUTS), including urinary&#xD;
      frequency, urgency, nocturia (getting up at night during sleep to urinate), decreased or&#xD;
      intermittent force of stream, or a sensation of incomplete emptying. Complications occur less&#xD;
      commonly but may include acute urinary retention, impaired bladder emptying, or the need for&#xD;
      surgery.&#xD;
&#xD;
      In current clinical practice, most patients are initially treated with medical therapy,&#xD;
      usually with alpha-blockers. A minimally invasive treatment alternative is the use of&#xD;
      urethral stents to preserve flow of urine from the bladder. Such stents are also associated&#xD;
      with several problems such as encrustation, stone formation, pain, infection, migration and&#xD;
      others. Another alternative is the gold standard treatment for managing benign prostatic&#xD;
      hyperplasia; the trans urethral resection of prostate (TURP) surgery. Complications associate&#xD;
      with TURP procedure include retrograde ejaculation, urinary incontinence, erectile&#xD;
      dysfunction, urethral stricture, and others.&#xD;
&#xD;
      The Butterfly Medical Prostatic Retraction Device is a definitive device intended for&#xD;
      transurethral insertion into the male prostatic urethra diagnosed with Bladder Outlet&#xD;
      Obstruction (BOO), caused by an enlarged prostate gland. It is a single use device intended&#xD;
      to remain permanently in the prostate urethra, to open the occluded urethral passage. The&#xD;
      Butterfly device has a specific shape adjusted to fit the prostatic urethral lumen, and is&#xD;
      designed to reside only in the prostate urethra without migration to the urinary bladder or&#xD;
      the bulbar urethra. Unlike other forms of treatment, the Butterfly device does not inflict&#xD;
      any damage to the bladder neck, preventing irritation or retrograde ejaculation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reported device related adverse events</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Assess the rate, nature and severity of device-related adverse events reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystoscopic assessment - inflammation</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Cystoscopic assessment to evaluate lack of local inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystoscopic assessment - incrustations</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Cystoscopic assessment to evaluate no incrustations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystoscopic assessment - implant coverage</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Cystoscopic assessment to evaluate coverage by mucosa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device migration</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Rate of migration of the Butterfly device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms reduction - IPSS</measure>
    <time_frame>Baseline to 12 months post procedure</time_frame>
    <description>Improvement in IPSS at 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms reduction - Qmax</measure>
    <time_frame>Baseline to 12 months post procedure</time_frame>
    <description>Improvement in Qmax (by uroflowmetry) at 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual quality of life evaluation - erectile dysfunction</measure>
    <time_frame>12 month post procedure</time_frame>
    <description>Rate of de-novo sustained erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual quality of life evaluation - retrograde ejaculation</measure>
    <time_frame>12 month post procedure</time_frame>
    <description>Rate of de-novo sustained retrograde ejaculation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>BPH</condition>
  <condition>BOO - Bladder Outflow Obstruction</condition>
  <arm_group>
    <arm_group_label>Butterfly device implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Butterfly device implantation will be performed following initial cystoscopy to evaluate prostate condition and rule out other pathologies.&#xD;
Following implant size selection, the Butterfly implant will be deployed and positioned through the cystoscope over-sheath. After deployment the cystoscope (with its optics) will be re-introduced into the urethra to examine the Butterfly device position.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Butterfly device implantation</intervention_name>
    <description>The Butterfly device will be positioned and deployed with cystoscopy guidance</description>
    <arm_group_label>Butterfly device implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 50 or older&#xD;
&#xD;
          2. Verified BPH with prostate size of at least 30 grams or of 25 mm.&#xD;
&#xD;
          3. Signed Informed Consent&#xD;
&#xD;
          4. Failure, intolerance or patient non-compliance of medical treatment&#xD;
&#xD;
          5. Patients suffering from LUTS symptoms of BPH (IPSS &gt;12, Qmax=&lt;13 ml/sec)&#xD;
&#xD;
          6. Patient's voided volume of at least 125 ml in uroflow test&#xD;
&#xD;
          7. Patients not eligible for surgery or refusing surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known sensitivity to Nickel&#xD;
&#xD;
          2. Active Prostatitis&#xD;
&#xD;
          3. Urethral strictures&#xD;
&#xD;
          4. Prior surgery of prostate (simple or radical)&#xD;
&#xD;
          5. Currently active bladder tumor&#xD;
&#xD;
          6. Suspected neurogenic urinary bladder&#xD;
&#xD;
          7. Suspected a-contractile bladder&#xD;
&#xD;
          8. Enlarged median lobe of prostate.&#xD;
&#xD;
          9. Bladder Neck stricture or contracture&#xD;
&#xD;
         10. Urethral pathology: diverticula, strictures, tumors, fistula&#xD;
&#xD;
         11. Clinically Significant urinary tract infection&#xD;
&#xD;
         12. Uncontrolled bleeding disorders&#xD;
&#xD;
         13. Uncontrolled diabetes mellitus&#xD;
&#xD;
         14. Severe medical diseases precluding a minimally invasive procedure&#xD;
&#xD;
         15. Present active urinary stone disease&#xD;
&#xD;
         16. Patients who are under anticoagulants therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vardit Segal, Ph.D.</last_name>
    <phone>+972524579178</phone>
    <email>vardit@butterfly-medical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Idan Geva</last_name>
    <phone>+972504043838</phone>
    <email>Idan.geva@butterfly-medical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shamir Medical Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amnon Zisman, Prof</last_name>
      <phone>+972-53-7346164</phone>
      <email>AmnonZ@shamir.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Naomi Guy-Mor</last_name>
      <phone>+972-54-5910071</phone>
      <email>naomig@shamir.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Amnon Zisman, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shmuel Roizman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilla Cohen</last_name>
      <phone>+972-4-825-0843</phone>
      <email>HillaCo@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Mhran Kabha, Dr.</last_name>
      <phone>+972-58-7300815</phone>
      <email>kabha.mhran@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tal May, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maharan Kabha, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>H̱olon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Tsivian, Dr.</last_name>
      <phone>+972-3-5028659</phone>
      <email>atsivian@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gali Boratnic</last_name>
      <phone>+972-3-5028408</phone>
      <email>scurology@wmc.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Tsivian, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shachar Aharoni, Dr.</last_name>
      <phone>+972-3-9376558</phone>
      <email>shacharA3@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Inbal Grossman</last_name>
      <email>inbalgr3@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Shachar Aharoni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rina Labiner</last_name>
      <phone>+972-54-5630853</phone>
      <email>rinala1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Dan Leibovici, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Tsefat</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ran Katz, Dr.</last_name>
      <phone>+972-4-6828775</phone>
      <email>ran.k@ziv.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Yara Sefadi</last_name>
      <phone>+972-77-6828597</phone>
      <email>yara.s@ziv.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Ran Katz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 7, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>BOO</keyword>
  <keyword>Enlarged prostate</keyword>
  <keyword>LUTS</keyword>
  <keyword>Urinary obstruction</keyword>
  <keyword>Retrograde ejaculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

